Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis
-
Corresponding author:
Zhiyong Deng, 13888158986@163.com
;
-
Received Date:
2014-02-13
-
Abstract
Objective To discuss the clinical effects of radionuclide 89SrCL2 combined zoledronic acid treatment for hormone dependent breast neoplasm metastatic osteoma. Methods Clinical data of 64 patients with hormone dependent breast neoplasm metastatic osteoma were analyzed retrospectively.All of these patients were divided into 3 groups: one group of 22 cases treated with 89SrCL2(89SrCL2 group); another group of 21 cases treated with zoledronic acid(zoledronic acid group); and the last group of 21 cases treated with 89SrCL2 and zoledronic acid(combination group).Then patients′ metastatic lesion curative effects, the condition of bone pain remission, quality of life and bone marrow inhibitory reaction after treatment were observed. Results The effective rate, visual analogue scale decline rate, whole body KPS score increase rate and bone marrow inhibitory reaction rate of the 89SrCL2 group were 36.4%(8/22), 77.3%(17/22), 63.6%(14/22), 27.2%(6/22), and which were 33.3%(7/21), 71.4%(15/21), 52.4%(11/21), 19.0%(4/21) and 42.9%(9/21), 90.5%(19/21), 90.5%(19/21), 33.3%(7/21) in zoledronic acid group and combination group respectively. Conclusion 89SrCL2 combined with zoledronic acid on treating hormone dependent breast neoplasm metastatic osteoma has significant curative effect, and can relieve pain with less adverse reactions, and the combined treatment effects are better than that of 89SrCL2 or zoledronic acid alone.
-
-
References
[1]
|
Kozlow W, Guise TA.Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy[J].J Mammary Gland Biol Neoplasia, 2005, 10(2): 169-180. |
[2]
|
Mundy GR.Metastasis to bone: causes, consequences and therapeutic opportunities[J].Nat Rev Cancer, 2002, 2(8): 584-593. |
[3]
|
吕靖, 马彩玲.绝经后骨质疏松症的治疗新进展[J].医学综述, 2007, 13(1): 62-63. |
[4]
|
刘鹏熙, 周瑞芳, 许锐, 等.唑来膦酸与帕米膦酸二钠治疗乳腺癌骨转移性疼痛的近期疗效观察[J/OL].中华乳腺病杂志: 电子版, 2008, (4): 402-406[2014-01-13].http://cjbd.xnyy.cn/cn/index.asp. |
[5]
|
Finlay IG, Mason MD, Shelley M.Radioisotopes for the palliation of metastatic bone cancer: a systematic review[J].Lancet Oncol, 2005, 6(6): 392-400. |
[6]
|
潘中允.放射性核素治疗学[M].北京:人民卫生出版社, 2006: 217. |
[7]
|
翟士军, 万卫星, 吴娜静, 等.89SrCL2联合唑来膦酸治疗转移性骨肿瘤的疗效观察[J].中国辐射卫生, 2013, 22(4): 404-406. |
[8]
|
Body JJ.Clinical research update; zoledronate[J].Cancer, 1997, 80(8 Suppl): S1699-1701. |
[9]
|
Skerjance A, Berenson J, Hsu C, et al.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol, 2003, 43(2): 154-162. |
[10]
|
Neville-Webbe HI, Coleman RE.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med, 2003, 17(6): 539-553. |
[11]
|
Matsumoto S, Kimuta S, Seqawa H, et al.Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines[J].Lung Cancer, 2005, 47(1): 31-39. |
[12]
|
Croucher P, Jagdev S, Coleman R.The anti-tumor potential of zoledronic acid[J].Breast, 2003, 12 Suppl 2: S30-36. |
-
-
Proportional views
-